GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy
The purpose of this study is to test the ease of using a new device, called the GlowCap that reminds the patient to take their breast cancer hormone pill. The study will collect information about the experience with this device and what the patient thinks of its role in the daily pill taking routine.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Feasibility of Using the GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy|
- Assess the usability of the GlowCap system by patients [ Time Frame: 2 years ] [ Designated as safety issue: No ]>60 years of age with early stage breast cancer.
- Measure the acceptance and satisfaction of the GlowCap reminder system [ Time Frame: 2 years ] [ Designated as safety issue: No ]with respect to medication adherence in patients >60 years with early stage breast cancer taking adjuvant endocrine therapy.
|Study Start Date:||November 2010|
|Study Completion Date:||November 2011|
|Primary Completion Date:||October 2011 (Final data collection date for primary outcome measure)|
breast cancer patients taking endocrine therapy
Breast cancer patients, currently taking adjuvant endocrine therapy will be equipped with a GlowCap device for a period of 30 days. The GlowCap will become part of their medication taking routine.
Other: GlowCap device
Participants will be provided with a device called the GlowCap for a period of 30 days. The device has visual and auditory cues to help patients remember to take their medication at the same time each day. The GlowCap will be programmed to glow when it is time for each patient to take her medication. The GlowCap will initially glow bright orange for the first hour from the time the patient is scheduled to take the medication. During the second hour, the GlowCap system will play music in addition to continuing to glow. If after 2 hours the patient still has not opened the medication bottle, she will receive a phone call reminding her to take her medication.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01239251
|United States, New York|
|Memorial Sloan Kettering Cancer Center 1275 York Avenue|
|New York, New York, United States, 10065|
|Principal Investigator:||Tiffany Traina, MD||Memorial Sloan Kettering Cancer Center.|